.png)
.svg)
A medical device may be engineered to a single design specification, manufactured under a unified quality system, and validated to the same performance standards globally.
However, its regulatory pathway varies significantly depending on the market in which it is placed.
Consider a ventilator. While its intended use, essential performance, and risk profile remain constant, the regulatory requirements differ across jurisdictions:
- In India, compliance requires licensing under MDR 2017 through CDSCO.
- In the United States, market access depends on the appropriate FDA pathway — 510(k), De Novo, or PMA.
- In the European Union, CE marking under EU MDR is mandatory, often involving Notified Body assessment.
- In Canada, a Medical Device License (MDL) must be obtained from Health Canada.
- In Australia, inclusion in the ARTG via TGA is required.
- In Japan, Foreign Manufacturer Registration and MAH/D-MAH obligations apply.
Although global regulatory systems share common principles — risk-based classification, clinical evaluation, quality management systems, and post-market surveillance — their procedural structures, documentation formats, review mechanisms, and reporting timelines differ substantially.
For Quality and Regulatory professionals, this underscores an important reality: regulatory compliance is jurisdiction specific. Approval in one region does not equate to automatic acceptance elsewhere. Each authority evaluates safety, performance, and conformity within its own legal and procedural framework.
Therefore, successful global market access requires early regulatory strategy, alignment of technical documentation, robust risk management, and adaptable quality systems capable of supporting multi-country submissions.
In medical technology, product performance may be universal.
Regulatory execution is not.
For more information, visit https://eemedicals.com/
.svg)
.svg)
.svg)